Category: St. Jude Medical
A Danish study of St. Jude Medical's recalled Riata and Riata ST defibrillator leads suggests that the externalization problem that led to the recall worsens over time and is linked to "electrical abnormalities."
Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B
St. Jude Medical's 2nd-quarter results, including a 2% gain for its implantable cardiac defibrillator business, could signal a rebound for the ICD sector overall, according to Leerink Partners.
St. Jude Medical enters the spinal pain treatment arena with the $200 million cash acquisition of NeuroTherm and its radiofrequency ablation technology.
Minnesota-based medtech giant St. Jude Medical (NYSE:STJ) is broaching new ground in the spinal pain market with the $200 million acquisition of NeuroTherm, maker of radiofrequency ablation therapies.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA aims to stay the course in new 4-year plan; Medical device recalls for June 2014; Medtronic issues Class I recall of Duet neuro drainage and monitoring systems; FDA warns Staar Surgical for missing documentation; FDA clears St. Jude Medical after 2013 warning letter
MassDevice.com speaks to 3M's Deb Rectenwald, St. Jude Medical's Philip Ebeling and Nadim Yared, CEO of CVRx, about the environment for M&A in medtech following the $43 billion Medtronic/Covidien deal.